Holen Sie sich die Stockscreener-App
1.69
2.87%
-0.05
Schlusskurs vom Vortag:
$1.74
Offen:
$1.66
24-Stunden-Volumen:
82,191
Relative Volume:
0.35
Marktkapitalisierung:
$12.83M
Einnahmen:
Nettoeinkommen (Verlust:
KGV:
-
EPS:
-
Netto-Cashflow:
1W Leistung:
-5.59%
1M Leistung:
-20.28%
6M Leistung:
+0.00%
1J Leistung:
+0.00%
1-Tages-Spanne:
$0.00
$0.00
1-Wochen-Bereich:
$1.55
$1.96
52-Wochen-Spanne:
$1.485
$4.1599
Cerenome, Inc. Common Stock Stock (CNSY) Company Profile
Firmenname
Cerenome, Inc. Common Stock
Sektor
Branche
Telefon
-
Adresse
-
Compare CNSY vs VRTX, MRNA, REGN, ARGX, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CNSY
Cerenome, Inc. Common Stock
|
1.69 | 12.83M | 0 | 0 | 0 | 0.00 |
VRTX
Vertex Pharmaceuticals Inc
|
508.75 | 128.95B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
236.50 | 94.42B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
796.34 | 81.99B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
846.27 | 53.22B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
374.08 | 42.32B | 5.76B | 514.49M | 1.10B | 4.4813 |
Cerenome, Inc. Common Stock Stock (CNSY) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-02-03 | Eingeleitet | Lake Street | Buy |
| 2025-09-03 | Hochstufung | D. Boral Capital | Hold → Buy |
| 2025-03-17 | Eingeleitet | D. Boral Capital | Buy |
| 2021-01-25 | Eingeleitet | Ladenburg Thalmann | Buy |
| 2020-10-16 | Eingeleitet | Maxim Group | Buy |
Cerenome, Inc. Common Stock Aktie (CNSY) Neueste Nachrichten
New Strong Sell Stocks for October 15th - Zacks Investment Research
Form 4 Cerenome, Inc For: 1 October By Investing.com - Investing.com Canada
Form 4 Cerenome, Inc For: 1 October - Investing.com India
Form 4 Cerenome, Inc For: 1 October By Investing.com - Investing.com UK
After stock grant vesting, Cerenome (CNSY) director Kyle Guse holds 1,843 shares directly. - Stock Titan
Three stock grants vest, giving Cerenome (CNSY)'s CFO 2,985 common shares. - Stock Titan
After acquiring 921 shares, Cerenome (CNSY) director holds 1,843 shares directly. - Stock Titan
Three stock grants vest as Cerenome (CNSY) CEO Hedrick acquires 6,387, 8,066 and 1,986 shares. - Stock Titan
A director acquires 921 shares as Cerenome (CNSY) stock grants vest, bringing direct holdings to 1,843. - Stock Titan
A stock grant vests at Cerenome (CNSY). Director Hawkins acquires 921 shares and holds 2,450 common shares. - Stock Titan
Form 4 Cerenome, Inc For: 1 October By Investing.com - Investing.com South Africa
Cerenome, Inc. (CNSY) Stock Price, News, Quote & History - Yahoo! Finance Canada
Cerenome, Inc. (CNSY) stock price, news, quote and history - Yahoo Finance UK
Cerenome plans to discuss billing and access for its spinal-fluid diagnostic platform. - Stock Titan
ServiceNow To Rally More Than 18%? Here Are 10 Top Analyst Forecasts For Friday - Benzinga
Cerenome forecasts its cash will last into 2028 with new financing - Stock Titan
Cerenome, Inc. announced that it expects to receive $20 million in funding from 3i Fund - marketscreener.com
Cerenome Launches New Corporate Identity As Integrated CNS Oncology Company | News - Voice of Alexandria
CNSY | Cerenome, Inc. Common Stock Stock Data, Price & News - Quiver Quantitative
Cerenome Reports Second Quarter 2026 Financial Results and Business Update - The Manila Times
What is the current Price Target and Forecast for Cerenome, Inc. (CNSY) - Zacks Investment Research
Cerenome, Inc. Stock (CNSY)Quote Nasdaq - marketscreener.com
CNSY Forecast — Price Target — Prediction for 2027 - TradingView
Cerenome (Nasdaq:CNSY)주식 분석 - simplywall.st
Cerenome (Nasdaq:CNSY)Stock Analysis - Simply Wall Street
CNSY Stock Price and Chart — NASDAQ:CNSY - tradingview.com
CNSYCerenome Inc Stock Price and Quote - Finviz
Plus Therapeutics, Inc. will Change its Ticker to CNSY from PSTV - marketscreener.com
Cerenome will combine CNS cancer diagnostics, treatments and AI Aug. 3 - Stock Titan
Cerenome Launches as an Integrated CNS Oncology Company - GlobeNewswire
Cerenome Launches as an Integrated CNS Oncology Company - Yahoo Finance
Plus Therapeutics' CNSide Tests Influenced Treatment Decisions in 90% of Cases - Stock Titan
Plus Therapeutics to rebrand as Cerenome and adopt CNSY ticker on August 3 (PSTV) - finance.yahoo.com
Plus Therapeutics to rebrand as Cerenome, change ticker to CNSY - Investing.com
Plus Therapeutics Provides Mid-Year Business Update Including Corporate Rebranding - GlobeNewswire
Plus Therapeutics Reports First Quarter 2026 Financial - GlobeNewswire
Plus Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement - GlobeNewswire
Plus Therapeutics taps ex-Kiora executive to help push CNS cancer pipeline - Stock Titan
To keep its Nasdaq listing, Plus Therapeutics enacts 1-for-25 split - Stock Titan
Plus Therapeutics Announces Reverse Stock Split - GlobeNewswire
Plus Therapeutics Reports Granting of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Plus Therapeutics Reports 2025 Results, Business Progress - GlobeNewswire
HIND Stock Price and Chart — NASDAQ:HIND - TradingView
LTRN Stock Price and Chart — NASDAQ:LTRN - tradingview.com
PLUS THERAPEUTICS (PSTV) Stock Price, News & Analysis - Stock Titan
EGRX Stock Price and Chart — OTC:EGRX - TradingView
ACTU Stock Price and Chart — NASDAQ:ACTU - TradingView
Finanzdaten der Cerenome, Inc. Common Stock-Aktie (CNSY)
Es liegen keine Finanzdaten für Cerenome, Inc. Common Stock (CNSY) vor. Überprüfen Sie andere Aktien für weitere Informationen.
Umsatz
Nettogewinn
Free Cashflow
ENV
Cerenome, Inc. Common Stock-Aktie (CNSY) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Guse Kyle | Director |
Oct 01 '26 |
Option Exercise |
0.00 |
921 |
0 |
1,843 |
| Hawkins Richard J | Director |
Oct 01 '26 |
Option Exercise |
0.00 |
921 |
0 |
2,450 |
| Sims Andrew John Hugh MacIntyr | Chief Financial Officer |
Oct 01 '26 |
Option Exercise |
0.00 |
2,985 |
0 |
12,926 |
| Clowes Howard | Director |
Oct 01 '26 |
Option Exercise |
0.00 |
921 |
0 |
2,902 |
| HEDRICK MARC H | Chief Executive Officer |
Oct 01 '26 |
Option Exercise |
0.00 |
16,439 |
0 |
60,922 |
| ANDREWS RONALD ASBURY | Director |
Oct 01 '26 |
Option Exercise |
0.00 |
921 |
0 |
1,843 |
| ANDREWS RONALD ASBURY | Director |
Jul 01 '26 |
Option Exercise |
0.00 |
922 |
0 |
922 |
| van Es-Johansson An | Director |
Jul 01 '26 |
Option Exercise |
0.00 |
922 |
0 |
922 |
| HEDRICK MARC H | Chief Executive Officer |
Jul 01 '26 |
Option Exercise |
0.00 |
16,439 |
0 |
44,483 |
| Clowes Howard | Director |
Jul 01 '26 |
Option Exercise |
0.00 |
922 |
0 |
1,981 |
1.35%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):